219 related articles for article (PubMed ID: 15781125)
1. The efficacy of cidofovir treatment of mice infected with ectromelia (mousepox) virus encoding interleukin-4.
Robbins SJ; Jackson RJ; Fenner F; Beaton S; Medveczky J; Ramshaw IA; Ramsay AJ
Antiviral Res; 2005 Apr; 66(1):1-7. PubMed ID: 15781125
[TBL] [Abstract][Full Text] [Related]
2. A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease.
Israely T; Paran N; Lustig S; Erez N; Politi B; Shafferman A; Melamed S
Virol J; 2012 Jun; 9():119. PubMed ID: 22709563
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model.
Buller RM; Owens G; Schriewer J; Melman L; Beadle JR; Hostetler KY
Virology; 2004 Jan; 318(2):474-81. PubMed ID: 14972516
[TBL] [Abstract][Full Text] [Related]
4. Deficiency in Th2 cytokine responses exacerbate orthopoxvirus infection.
Sakala IG; Chaudhri G; Eldi P; Buller RM; Karupiah G
PLoS One; 2015; 10(3):e0118685. PubMed ID: 25751266
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model.
Parker S; Touchette E; Oberle C; Almond M; Robertson A; Trost LC; Lampert B; Painter G; Buller RM
Antiviral Res; 2008 Jan; 77(1):39-49. PubMed ID: 17904231
[TBL] [Abstract][Full Text] [Related]
6. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox.
Jackson RJ; Ramsay AJ; Christensen CD; Beaton S; Hall DF; Ramshaw IA
J Virol; 2001 Feb; 75(3):1205-10. PubMed ID: 11152493
[TBL] [Abstract][Full Text] [Related]
7. Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis, and antiviral therapy.
Chen N; Bellone CJ; Schriewer J; Owens G; Fredrickson T; Parker S; Buller RM
Virology; 2011 Jan; 409(2):328-37. PubMed ID: 21071055
[TBL] [Abstract][Full Text] [Related]
8. Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies.
Parker S; Siddiqui AM; Oberle C; Hembrador E; Lanier R; Painter G; Robertson A; Buller RM
Virology; 2009 Mar; 385(1):11-21. PubMed ID: 19100593
[TBL] [Abstract][Full Text] [Related]
9. Loss of Resistance to Mousepox during Chronic Lymphocytic Choriomeningitis Virus Infection Is Associated with Impaired T-Cell Responses and Can Be Rescued by Immunization.
Alves-Peixoto P; Férez M; Knudson CJ; Melo-Silva CR; Stotesbury C; Wong EB; Correia-Neves M; Sigal LJ
J Virol; 2020 Feb; 94(5):. PubMed ID: 31826990
[TBL] [Abstract][Full Text] [Related]
10. Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus.
Parker S; Crump R; Foster S; Hartzler H; Hembrador E; Lanier ER; Painter G; Schriewer J; Trost LC; Buller RM
Antiviral Res; 2014 Nov; 111():42-52. PubMed ID: 25128688
[TBL] [Abstract][Full Text] [Related]
11. Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.
Parker S; Schriewer J; Oberle C; Robertson A; Lanier R; Painter G; Buller RM
Antivir Ther; 2008; 13(7):863-73. PubMed ID: 19043920
[TBL] [Abstract][Full Text] [Related]
12. Buccal viral DNA as a trigger for brincidofovir therapy in the mousepox model of smallpox.
Crump R; Korom M; Buller RM; Parker S
Antiviral Res; 2017 Mar; 139():112-116. PubMed ID: 28039021
[TBL] [Abstract][Full Text] [Related]
13. Redundant Function of Plasmacytoid and Conventional Dendritic Cells Is Required To Survive a Natural Virus Infection.
Kaminsky LW; Sei JJ; Parekh NJ; Davies ML; Reider IE; Krouse TE; Norbury CC
J Virol; 2015 Oct; 89(19):9974-85. PubMed ID: 26202250
[TBL] [Abstract][Full Text] [Related]
14. Chronic Lymphocytic Choriomeningitis Infection Causes Susceptibility to Mousepox and Impairs Natural Killer Cell Maturation and Function.
Alves-Peixoto P; Férez M; Knudson CJ; Stotesbury C; Melo-Silva CR; Wong EB; Correia-Neves M; Sigal LJ
J Virol; 2020 Feb; 94(5):. PubMed ID: 31776282
[TBL] [Abstract][Full Text] [Related]
15. Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox.
Chaudhri G; Panchanathan V; Buller RM; van den Eertwegh AJ; Claassen E; Zhou J; de Chazal R; Laman JD; Karupiah G
Proc Natl Acad Sci U S A; 2004 Jun; 101(24):9057-62. PubMed ID: 15184649
[TBL] [Abstract][Full Text] [Related]
16. T cell cytokine synthesis at the single-cell level in BALB/c and C57BL/6 mice infected with ectromelia virus.
Szulc L; Gieryńska M; Winnicka A; Martyniszyn L; Boratyńska-Jasińska A; Niemiałtowski M
Postepy Hig Med Dosw (Online); 2012 Apr; 66():222-30. PubMed ID: 22706108
[TBL] [Abstract][Full Text] [Related]
17. Oral 1-O-octadecyl-2-O-benzyl-sn-glycero-3-cidofovir targets the lung and is effective against a lethal respiratory challenge with ectromelia virus in mice.
Hostetler KY; Beadle JR; Trahan J; Aldern KA; Owens G; Schriewer J; Melman L; Buller RM
Antiviral Res; 2007 Mar; 73(3):212-8. PubMed ID: 17123638
[TBL] [Abstract][Full Text] [Related]
18. A method for the generation of ectromelia virus (ECTV) recombinants: in vivo analysis of ECTV vCD30 deletion mutants.
Alejo A; Saraiva M; Ruiz-Argüello MB; Viejo-Borbolla A; de Marco MF; Salguero FJ; Alcami A
PLoS One; 2009; 4(4):e5175. PubMed ID: 19365546
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections.
De Clercq E
Verh K Acad Geneeskd Belg; 1996; 58(1):19-47; discussion 47-9. PubMed ID: 8701600
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox.
Parker S; Chen NG; Foster S; Hartzler H; Hembrador E; Hruby D; Jordan R; Lanier R; Painter G; Painter W; Sagartz JE; Schriewer J; Mark Buller R
Antiviral Res; 2012 Apr; 94(1):44-53. PubMed ID: 22381921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
